Holen Sie sich die Stockscreener-App
1.38
0.72%
-0.01
Handel nachbörslich:
1.38
Schlusskurs vom Vortag:
$1.39
Offen:
$1.4
24-Stunden-Volumen:
95,126
Relative Volume:
0.22
Marktkapitalisierung:
$83.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.86M
KGV:
-1.2321
EPS:
-1.12
Netto-Cashflow:
$-55.66M
1W Leistung:
+5.34%
1M Leistung:
+3.76%
6M Leistung:
+14.05%
1J Leistung:
-42.50%
1-Tages-Spanne:
$1.335
$1.40
1-Wochen-Bereich:
$1.30
$1.43
52-Wochen-Spanne:
$0.8551
$3.36
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Firmenname
Acumen Pharmaceuticals Inc
Sektor
Branche
Telefon
617-344-4190
Adresse
1210-1220 WASHINGTON STREET, NEWTON
Vergleichen Sie ABOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.38 | 82.38M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-07-26 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-20 | Fortgesetzt | BofA Securities | Buy |
| 2023-05-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Eingeleitet | BTIG Research | Buy |
| 2022-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-07-26 | Eingeleitet | BofA Securities | Neutral |
| 2021-07-26 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-26 | Eingeleitet | Stifel | Buy |
| 2021-07-26 | Eingeleitet | UBS | Buy |
Alle ansehen
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Can Acumen Pharmaceuticals Inc. recover in the next quarterTrend Reversal & Expert Verified Stock Movement Alerts - Newser
News impact scoring models applied to Acumen Pharmaceuticals Inc.July 2025 PostEarnings & Weekly Hot Stock Watchlists - Newser
Can Acumen Pharmaceuticals Inc. ride the EV waveMarket Activity Report & Expert Verified Movement Alerts - khodrobank.com
Will earnings trigger a reversal in Acumen Pharmaceuticals Inc.July 2025 Update & Accurate Intraday Trading Signals - Newser
Is Acumen Pharmaceuticals Inc. building a consolidation baseAnalyst Upgrade & Short-Term High Return Strategies - Newser
Is Acumen Pharmaceuticals Inc. a play on infrastructure spendingJuly 2025 Volume & Weekly High Momentum Picks - khodrobank.com
What to expect from Acumen Pharmaceuticals Inc. in the next 30 daysIndex Update & AI Driven Price Forecasts - Newser
Will Acumen Pharmaceuticals Inc. rebound enough to break evenWeekly Market Report & Comprehensive Market Scan Reports - Newser
Short interest data insights for Acumen Pharmaceuticals Inc.Market Rally & Expert-Curated Trade Recommendations - Newser
Can Acumen Pharmaceuticals Inc. expand into new marketsGap Up & Low Risk Investment Opportunities - khodrobank.com
Is Acumen Pharmaceuticals Inc. stock ready for a breakoutJuly 2025 Institutional & Accurate Technical Buy Alerts - Newser
Volume spikes in Acumen Pharmaceuticals Inc. stock – what they meanGlobal Markets & Smart Money Movement Tracker - Newser
Acumen Pharmaceuticals at Citi’s Biopharma: Strategic Insights on Alzheimer’s - Investing.com
What MACD signals say about Acumen Pharmaceuticals Inc.2025 Sector Review & Technical Analysis for Trade Confirmation - Newser
Acumen Pharmaceuticals’ Earnings Call Highlights Strategic Growth - MSN
Leading vs lagging indicators on Acumen Pharmaceuticals Inc. performanceMarket Movement Recap & Safe Entry Momentum Tips - Newser
What’s next for Acumen Pharmaceuticals Inc. stockCEO Change & Fast Exit Strategy with Risk Control - khodrobank.com
Acumen Pharmaceuticals' Q2 Earnings Call Highlights Strategic Growth and Alzheimer's Therapy Advancements - AInvest
Is Acumen Pharmaceuticals Inc. stock a good pick for beginnersJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - khodrobank.com
Market reaction to Acumen Pharmaceuticals Inc.’s recent newsQuarterly Profit Summary & Reliable Trade Execution Plans - Newser
What machine learning models say about Acumen Pharmaceuticals Inc.2025 Macro Impact & Weekly Chart Analysis and Guides - Newser
Applying Wyckoff theory to Acumen Pharmaceuticals Inc. stockWeekly Volume Report & High Conviction Buy Zone Picks - Newser
Multi factor analysis applied to Acumen Pharmaceuticals Inc.Portfolio Update Report & Proven Capital Preservation Methods - Newser
Multi factor analysis applied to Acumen Pharmaceuticals IncMarket Trend Report & Verified Stock Trade Ideas - Newser
Acumen Pharmaceuticals Inc. Consolidation Zone May Signal Accumulation getLinesFromResByArray error: size == 0 - kangso.co.kr
Acumen Pharmaceuticals Inc. stock outlook for YEAR2025 Analyst Calls & Consistent Profit Trading Strategies - Newser
Technical analysis overview for Acumen Pharmaceuticals Inc. stockGDP Growth & Daily Entry Point Trade Alerts - Newser
Earnings visualization tools for Acumen Pharmaceuticals Inc.2025 Dividend Review & Community Driven Trade Alerts - Newser
Is this a good reentry point in Acumen Pharmaceuticals Inc.Quarterly Market Review & Daily Price Action Insights - Newser
What institutional flow reveals about Acumen Pharmaceuticals Inc.Trade Entry Summary & Long Hold Capital Preservation Tips - Newser
How high can Acumen Pharmaceuticals Inc. stock goMarket Growth Summary & Weekly Setup with High ROI Potential - Newser
Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acumen Pharmaceuticals Inc-Aktie (ABOS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):